SNWV vs ANIK

For growth investors, SANUWAVE Health, Inc.

(SNWV) is the stronger pick with 60. 0% revenue growth year-over-year, versus -5. 9% for Anika Therapeutics, Inc. (ANIK). Analysts rate SANUWAVE Health, Inc. (SNWV) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Anika Therapeutics, Inc.

(ANIK) delivered a total return of -63. 9%, compared to -72. 2% for SANUWAVE Health, Inc. (SNWV). Over 10 years, the gap is even starker: SNWV returned -20. 7% versus ANIK's -65. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Anika Therapeutics, Inc.

(ANIK) is the lower-risk stock at 1. 14β versus SANUWAVE Health, Inc. 's 1. 22β — meaning SNWV is approximately 7% more volatile than ANIK relative to the S&P 500.

By revenue growth (latest reported year), SANUWAVE Health, Inc.

(SNWV) is pulling ahead at 60. 0% versus -5. 9% for Anika Therapeutics, Inc. (ANIK). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to 42. 3% for SANUWAVE Health, Inc.. Over a 3-year CAGR, SNWV leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Anika Therapeutics, Inc.

(ANIK) is the more profitable company, earning -9. 6% net margin versus -96. 1% for SANUWAVE Health, Inc. — meaning it keeps -9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNWV leads at 16. 6% versus -9. 8% for ANIK. At the gross margin level — before operating expenses — SNWV leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Anika Therapeutics, Inc.

(ANIK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). Both have compounded well over 10 years (ANIK: -65. 9%, SNWV: -20. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNWV is a small-cap high-growth stock; ANIK is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.